Strasbourg, France, December 18, 2017, 6:00 pm CET - Transgene (Euronext Paris: TNG) today announces that Management will participate in the upcoming investor events set out below.
Transgene will meet institutional investors from January 7 to 11, 2018, in San Francisco, USA, concurrent with the J.P. Morgan Healthcare conference.
The Company will also attend:
• Oddo Forum: January 11 & 12, 2018 - Lyon, France
• Portzamparc MidCap Conference: April 4, 2018 - Paris, France
• Small Cap Event: April 16 & 17, 2018 - Paris, France
• Kempen Life Sciences Conference: April 18 & 19, 2018 - Amsterdam, Netherlands
Contacts
Transgene:
Media contacts:
Lucie Larguier
Citigate Dewe Rogerson
Director Corporate Communications & IR
David Dible / Marine Perrier
+33 (0)3 88 27 91 04
+ 44 (0)20 7638 9571
investorrelations@transgene.fr
transgene@citigatedr.co.uk
About Transgene
Transgene (Euronext Paris: TNG), part of Institut Mérieux, is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company's lead clinical-stage programs are: TG4010, a therapeutic vaccine against non-small cell lung cancer, Pexa-Vec, an oncolytic virus against liver cancer, and TG4001, a therapeutic vaccine against HPV-positive head and neck cancers. The Company has several other programs in clinical and preclinical development, including TG1050 (chronic hepatitis B) and TG6002 (solid tumors). Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as a joint venture in China.
Additional information about Transgene is available atwww.transgene.fr.Follow us on Twitter:@TransgeneSA
Transgene SA published this content on 18 December 2017 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 18 December 2017 17:09:05 UTC.
Original documenthttps://www.transgene.fr/wp-content/uploads/2017/12/20171218-PR-financial-agenda-T1-18.pdf
Public permalinkhttp://www.publicnow.com/view/78FE5AA92BEEE6FC53EEEAAFD1BE37AA97617FE9
Transgene, part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells.
Transgene has a portfolio of 5 products in clinical development: TG4050, the first individualized therapeutic vaccine based on the myvac® platform, TG4001 a therapeutic vaccine for HPV positive cancers, as well as TG6002, BT-001 and TG6050, three oncolytic viruses based on the Invir.IO® viral backbone. Transgene has several other programs in clinical and pre-clinical development that are based on its core viral vector technology.
Transgene is based in Strasbourg, France, and has additional operations in Lyon and China.
TRANSGENE 
